Literature DB >> 26610809

A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation.

Anna Sannino1, Giuseppe Gargiulo, Gabriele Giacomo Schiattarella, Cinzia Perrino, Eugenio Stabile, Maria-Angela Losi, Maurizio Galderisi, Raffaele Izzo, Giovanni de Simone, Bruno Trimarco, Giovanni Esposito.   

Abstract

AIMS: Little is known about the prognostic role of pre-existing atrial fibrillation (AF) and new-onset AF (NOAF) in transcatheter aortic valve implantation (TAVI). Therefore, the aim of this meta-analysis was to compare the short- and long-term clinical outcomes of patients undergoing TAVI with and without pre-existing and new-onset AF. METHODS AND
RESULTS: Twenty-six studies, enrolling 14,078 patients undergoing TAVI, of whom 33.4% had pre-existing AF and 17.5% had NOAF, were analysed for early and long-term all-cause mortality, cardiovascular mortality and cerebrovascular events (CVE). In patients with pre-existing AF, 30-day all-cause mortality was similar to patients in sinus rhythm (SR). Conversely, long-term all-cause and cardiovascular mortality were significantly greater in pre-existing AF patients than in patients with SR (20 studies; 8,743 patients; HR: 1.68; p<0.00001, and three studies; 1,138 patients; HR: 2.07; p=0.01, respectively). Pre-existing AF was not a predictor of CVE at long-term follow-up. NOAF patients showed similar short- and long-term all-cause mortality when compared to patients in SR, whereas they experienced a significantly higher incidence of CVE at short-term follow-up (six studies; 2,025 patients; HR: 2.86; p<0.00001). A non-significant increase in the incidence of CVE was observed at long-term follow-up.
CONCLUSIONS: Pre-existing AF is a predictor of all-cause mortality in patients undergoing TAVI. NOAF is related to the occurrence of CVE at short-term follow-up. Similarly to surgical aortic valve replacement (SAVR), the optimal management and risk stratification of these patients should be further investigated.

Entities:  

Mesh:

Year:  2016        PMID: 26610809     DOI: 10.4244/EIJY15M11_12

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  19 in total

1.  Deceleration capacity of heart rate predicts 1-year mortality of patients undergoing transcatheter aortic valve implantation.

Authors:  Martin Duckheim; Charlotte Bensch; Linn Kittlitz; Nin Götz; Katharina Klee; Patrick Groga-Bada; Lars Mizera; Meinrad Gawaz; Christine Zuern; Christian Eick
Journal:  Clin Cardiol       Date:  2017-08-28       Impact factor: 2.882

2.  Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle.

Authors:  Giuseppe Gargiulo; Marco Valgimigli
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 3.  Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?

Authors:  Emanuel Raschi; Matteo Bianchin; Cecilia Fantoni; Walter Ageno; Fabrizio De Ponti; Roberto De Ponti
Journal:  Intern Emerg Med       Date:  2017-08-07       Impact factor: 3.397

4.  Survival and Cardiovascular Outcomes of Patients With Secondary Mitral Regurgitation: A Systematic Review and Meta-analysis.

Authors:  Anna Sannino; Robert L Smith; Gabriele G Schiattarella; Bruno Trimarco; Giovanni Esposito; Paul A Grayburn
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

Review 5.  Diabetes mellitus is associated with increased acute kidney injury and 1-year mortality after transcatheter aortic valve replacement: A meta-analysis.

Authors:  George S Mina; Priyanka Gill; Demiana Soliman; Pratap Reddy; Paari Dominic
Journal:  Clin Cardiol       Date:  2017-05-16       Impact factor: 2.882

6.  Transapical transcatheter aortic valve replacement in patients with or without prior coronary artery bypass graft operation.

Authors:  Konstantinos V Voudris; S Chiu Wong; Ryan Kaple; Polydoros N Kampaktsis; Andreas R de Biasi; Jonathan S Weiss; Richard Devereux; Karl Krieger; Luke Kim; Rajesh V Swaminathan; Dmitriy N Feldman; Harsimran Singh; Nikolaos J Skubas; Robert M Minutello; Geoffrey Bergman; Arash Salemi
Journal:  J Cardiothorac Surg       Date:  2016-11-29       Impact factor: 1.637

7.  Incidence, pathophysiology, predictive factors and prognostic implications of new onset atrial fibrillation following transcatheter aortic valve implantation.

Authors:  Ioanna Koniari; Grigorios Tsigkas; Nikolaos Kounis; Dimitrios Velissaris; Emmanouil Chourdakis; Periklis Davlouros; George Hahalis
Journal:  J Geriatr Cardiol       Date:  2018-01       Impact factor: 3.327

Review 8.  Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status.

Authors:  Antonio Greco; Davide Capodanno
Journal:  Interv Cardiol       Date:  2020-04-23

9.  Trends and effect of atrial fibrillation on inpatient outcomes after transcatheter aortic valve replacement.

Authors:  Nikita Patil; Paula D Strassle; Sameer Arora; Chinmay Patel; Kishorbhai Gangani; John P Vavalle
Journal:  Cardiovasc Diagn Ther       Date:  2020-02

10.  Impact of leaflet thrombosis on hemodynamics and clinical outcomes after bioprosthetic aortic valve replacement: A meta-analysis.

Authors:  Zixin Tian; Tiejun Li; Shumei Ma
Journal:  Clin Cardiol       Date:  2020-01-20       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.